BPR-277

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameBPR-277
Drug Alias NameBPR-277LM-030
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPancreatic elastase inhibitors
TargetsPancreatic elastase
Therapy Area/IndicationsDermatitis, AtopicIchthyosiform Erythroderma, CongenitalNetherton Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlands
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsIchthyosiform Erythroderma, Congenital
Inactive IndicationsDermatitis, AtopicNetherton Syndrome

Other Information

ATC CodeN/A
Related LinksN/A